Levaquin is a brand name of levofloxacin, approved by the FDA in the following formulation(s):
LEVAQUIN (levofloxacin - injectable; injection)
Manufacturer: JANSSEN PHARMS
Approval date: December 20, 1996
Strength(s): EQ 500MG/20ML (EQ 25MG/ML) [RLD][AP], EQ 750MG/30ML (EQ 25MG/ML) [RLD][AP]
LEVAQUIN (levofloxacin - solution; oral)
Manufacturer: JANSSEN PHARMS
Approval date: October 21, 2004
Strength(s): 250MG/10ML [RLD][AA]
LEVAQUIN (levofloxacin - tablet; oral)
Manufacturer: JANSSEN PHARMS
Approval date: December 20, 1996
Strength(s): 250MG [AB], 500MG [AB]
Manufacturer: JANSSEN PHARMS
Approval date: September 8, 2000
Strength(s): 750MG [RLD][AB]
Has a generic version of Levaquin been approved?
A generic version of Levaquin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Levaquin and have been approved by the FDA:
levofloxacin injectable; injection
Manufacturer: AKORN
Approval date: June 20, 2011
Strength(s): EQ 500MG/20ML (EQ 25MG/ML) [AP], EQ 750MG/30ML (EQ 25MG/ML) [AP]
Manufacturer: SAGENT PHARMS
Approval date: June 20, 2011
Strength(s): EQ 500MG/20ML (EQ 25MG/ML) [AP], EQ 750MG/30ML (EQ 25MG/ML) [AP]
levofloxacin solution; oral
Manufacturer: HI TECH PHARMA
Approval date: June 20, 2011
Strength(s): 250MG/10ML [AA]
levofloxacin tablet; oral
Manufacturer: APOTEX INC
Approval date: September 29, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: AUROBINDO PHARMA LTD
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: DR REDDYS LABS INC
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: GLENMARK GENERICS
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: LUPIN
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: MYLAN
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: ORCHID HLTHCARE
Approval date: January 30, 2012
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: SANDOZ
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: TEVA
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: TORRENT PHARMS
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Manufacturer: WOCKHARDT
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levaquin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Taste masked liquid pharmaceutical compositions
Patent 6,806,256
Issued: October 19, 2004
Inventor(s): Stephen A.; Ulrich & Karen R.; Zimm & Marc Karel Jozef; Francois & Willy Maria Albert Carlo; Dries
Assignee(s): Ortho -McNeil Pharmaceutical, Inc.
This invention is directed to a taste masked liquid pharmaceutical composition comprising a pharmaceutically active agent and a taste masking composition. In particular, the taste masking composition comprises a taste masking effective amount of an artificial sweetener.Patent expiration dates:
- February 26, 2022✓
- August 26, 2022✓
- February 26, 2022
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 10, 2010 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- September 14, 2010 - TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- March 10, 2011 - PEDIATRIC EXCLUSIVITY
See also...
- Levaquin Consumer Information (Drugs.com)
- Levaquin Consumer Information (Wolters Kluwer)
- Levaquin Solution Consumer Information (Wolters Kluwer)
- Levaquin Tablets Consumer Information (Wolters Kluwer)
- Levaquin Consumer Information (Cerner Multum)
- Levaquin Advanced Consumer Information (Micromedex)
- Levaquin Intravenous Advanced Consumer Information (Micromedex)
- Levaquin AHFS DI Monographs (ASHP)
- Levofloxacin Consumer Information (Wolters Kluwer)
- Levofloxacin Solution Consumer Information (Wolters Kluwer)
- Levofloxacin Tablets Consumer Information (Wolters Kluwer)
- Levofloxacin Consumer Information (Cerner Multum)
- Levofloxacin Advanced Consumer Information (Micromedex)
- Levofloxacin Intravenous Advanced Consumer Information (Micromedex)
- Levofloxacin AHFS DI Monographs (ASHP)
No comments:
Post a Comment